Envestnet Asset Management Inc. Boosts Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Envestnet Asset Management Inc. boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 36.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 90,742 shares of the specialty pharmaceutical company's stock after purchasing an additional 24,443 shares during the period. Envestnet Asset Management Inc. owned about 0.15% of Jazz Pharmaceuticals worth $11,175,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. IFP Advisors Inc bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $25,000. CoreFirst Bank & Trust bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $28,000. Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $29,000. Jones Financial Companies Lllp lifted its stake in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 130 shares during the period. Finally, UMB Bank n.a. boosted its holdings in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after buying an additional 129 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded up $2.98 during mid-day trading on Wednesday, reaching $106.36. The stock had a trading volume of 100,460 shares, compared to its average volume of 1,007,746. The company has a market cap of $6.46 billion, a P/E ratio of 14.98, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The business's 50 day moving average price is $126.23 and its 200 day moving average price is $122.31. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, April 10th. Barclays reiterated an "overweight" rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Piper Sandler restated an "overweight" rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Royal Bank of Canada lowered their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Finally, HC Wainwright increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $187.71.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 1,140 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares of the company's stock, valued at $966,323.72. The trade was a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,023,305 in the last ninety days. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.